Four Ways to Build a Secure and Scalable CGT Distribution Network

Why It Matters

A robust CGT distribution framework reduces treatment delays, safeguards product integrity, and enables manufacturers to scale globally, directly influencing market adoption and revenue growth.

Key Takeaways

• 34 US cell and gene therapies approved as of April 2026
• Global CGT sales projected to hit $80 bn by 2029
• Fit‑for‑purpose channel design reduces patient travel and improves access
• Global logistics partners enable rapid expansion into new markets
• End‑to‑end traceability ensures temperature control and regulatory compliance

Pulse Analysis

The cell and gene therapy market is entering a period of unprecedented growth, with oncology accounting for nearly half of projected $80 bn sales by 2029. While scientific breakthroughs drive demand, the logistical reality of ultra‑cold shipping, short transport windows, and complex administration protocols creates a fragile supply chain. Companies that overlook these operational nuances risk delayed treatments, compromised product efficacy, and regulatory penalties, all of which can erode market share in a competitive landscape.

A fit‑for‑access channel strategy is essential for bridging the gap between patients and specialized treatment centers. By segmenting sites based on readiness—established CGT hubs, emerging facilities, and future candidates—manufacturers can align distribution coverage with real‑world capabilities. Incorporating referral pathways ensures that patients diagnosed in community settings can be efficiently routed to qualified infusion sites, reducing travel burdens and improving adherence. Partnering with a logistics provider that boasts a global footprint further amplifies reach, offering localized expertise, regulatory support, and pre‑validated evidence packages that smooth entry into new territories.

Supply‑chain resilience and end‑to‑end traceability round out the blueprint for scalable CGT distribution. Early validation of packaging compatibility, contingency playbooks, and continuous temperature monitoring mitigate the risk of costly delays. Advanced, platform‑agnostic software provides real‑time visibility of shipment location, custody handoffs, and temperature excursions, replacing error‑prone spreadsheets. Extending traceability into hospital compounding and administration workflows safeguards compliance and patient safety, positioning manufacturers to meet rising reimbursement pressures while delivering life‑changing therapies at scale.